Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 (P50 Clinical Trial Required)
ID: 350299Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/350299

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-284.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the Specialized Programs of Research Excellence (SPOREs) in Human Cancers, aimed at funding innovative P50 Research Center Grants for the years 2024, 2025, and 2026. This initiative focuses on supporting translational research that enhances prevention, early detection, diagnosis, and treatment of organ-specific cancers or closely related groups, with a requirement for clinical trials. The SPORE program is crucial for advancing cancer research and improving treatment outcomes, emphasizing collaboration, research infrastructure, and addressing health disparities. Interested applicants can apply starting December 25, 2023, with a maximum funding of $1.4 million in direct costs annually, and must submit their proposals by the specified deadlines in January, May, September, and January 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-284.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-284-Full-Announcement.html
    PAR-23-284.html
    The National Cancer Institute (NCI) announces a funding opportunity for Specialized Programs of Research Excellence (SPOREs) in Human Cancers spanning 2024 to 2026. This initiative invites applications for P50 Research Center Grants aimed at innovative translational research to improve cancer prevention, early detection, diagnosis, and treatment. The research should be focused on organ-specific cancers or related groups, and clinical trials are required. Key dates include an open application period beginning on December 25, 2023, with specific deadlines for submissions in January, May, September, and January 2026. Funds are available for approximately six to ten SPORE awards per year, with a maximum of $1.4 million in direct costs annually for projects meeting certain criteria. The SPORE program emphasizes collaboration, the establishment of research infrastructure, and engagement in cross-cutting themes such as health disparities. Applicants must demonstrate an ability to achieve translational human endpoints within five years and include a plan to enhance diversity. Each application must integrate core components: Administrative, Shared Resources, Developmental Research, and Career Enhancement programs. The document outlines detailed application instructions to ensure compliance and encourages engagement with NCI staff for guidance prior to submission. This call for proposals highlights the government's ongoing commitment to advancing cancer research and improving treatment outcomes through targeted funding initiatives.
    Similar Opportunities
    Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Minority Health (CHD-MH) (U54 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Minority Health (CHD-MH), under the funding opportunity RFA-CA-24-020. This initiative aims to establish a network of multidisciplinary programs dedicated to translational cancer research, specifically targeting prevention, early detection, treatment, and diagnosis in underserved populations affected by cancer. The program requires applicants to propose at least three research projects supported by comprehensive infrastructure, including various cores such as Administrative, Shared Resources, Developmental Research Program, and Career Enhancement Program, with a maximum budget request of $1.6 million annually over five years. Interested applicants must submit their proposals by September 27, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. The total funding available for this opportunity is approximately $80 million, expected to be distributed among around four awards.
    National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health, through the National Cancer Institute (NCI), invites applications for Program Project grants (P01) aimed at fostering collaborative, multidisciplinary cancer research for the years 2023, 2024, and 2025. Applicants must propose at least three interrelated research projects and an Administrative Core, all centered around a common theme within the expansive field of cancer research, which includes areas such as cancer biology, prevention, diagnosis, treatment, and control. This funding opportunity is crucial for advancing cancer research and enhancing the effectiveness of collaborative efforts, with applications due by May 7, 2026. Interested parties can find more information and application guidelines at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the "Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed)," aimed at enhancing the training of a workforce to meet the nation’s biomedical and clinical research needs, particularly in cancer research. This program seeks applications that propose innovative educational activities, specifically hands-on cancer research experiences lasting 8 to 15 weeks, complemented by additional educational initiatives. With a funding ceiling of $300,000 per year for a project period of up to five years, the program encourages participation from underrepresented groups and aims to provide unique educational opportunities not covered by existing programs. Interested applicants can find more information and guidelines at the NIH website, with the application deadline set for January 25, 2026.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (U34), aimed at facilitating well-planned clinical trials that enhance cancer prevention, treatment, and survivorship care. This funding opportunity seeks to address critical gaps in trial planning by acquiring essential data for finalizing protocols, including feasibility assessments and stakeholder engagement strategies. The program is particularly significant for improving cancer-related health behaviors and outcomes, with grants available up to $600,000 for trials including pilot studies, over a maximum of three years. Interested applicants, including higher education institutions and nonprofit organizations, must submit their proposals by September 7, 2025, and can direct inquiries to OERWebmaster03@od.nih.gov for further information.
    NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the NCI Small Grants Program for Cancer Research (R03) for the years 2023 to 2025. This funding opportunity is designed to support small-scale research projects on cancer that can be completed within a two-year timeframe and with limited resources, including pilot studies, secondary data analyses, and the development of research methodologies or technologies. Grants of up to $50,000 per year are available to a wide range of eligible applicants, including higher education institutions, nonprofits, and various community organizations. Interested parties should submit their applications electronically via Grants.gov, with the first submission deadline having been January 22, 2023, and subsequent deadlines continuing through 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research," aimed at advancing cancer research through the use of the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Biorepository. This initiative encourages applications that leverage high-quality, pre-diagnostic biospecimens and associated data to explore cancer risk factors and develop early detection biomarkers, emphasizing the unique characteristics of the PLCO resources. Eligible applicants include a diverse range of institutions, including historically black colleges, tribal colleges, and various community organizations, with no cost-sharing requirement. The application deadline is October 11, 2024, and interested parties can find more information and contact details at the NIH website or via email at OERWebmaster03@od.nih.gov.
    Research Projects in Physical Sciences-Oncology (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity for research projects that integrate physical sciences into oncology via a cooperative agreement mechanism (U01). The initiative, known as the Physical Sciences-Oncology Network (PS-ON), aims to foster transdisciplinary partnerships between physical scientists and cancer researchers to address significant cancer-related questions, with a focus on enhancing understanding and developing innovative solutions through a physical sciences approach. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and for-profit entities, with potential funding of up to $400,000 per year for a duration of five years. Interested parties should submit their applications by November 1, 2024, and can find more information and guidelines at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (R34), aimed at enhancing clinical trials focused on cancer prevention and control. This program seeks to address critical gaps in knowledge regarding study populations, interventions, and operational challenges, facilitating the collection of essential data to finalize protocols for future clinical trials. The initiative is particularly important for improving cancer-related health behaviors, screening, and the long-term outcomes of cancer survivors. Eligible applicants include a diverse range of organizations, with funding available up to $600,000 over three years, and applications are due by September 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Basic Research in Cancer Health Disparities" under the R21 Exploratory/Developmental Research Grant mechanism. This initiative aims to support innovative research investigating the biological and genetic factors contributing to cancer health disparities among various racial and ethnic populations, with a focus on mechanistic studies and the development of new methodologies. The program is designed to foster collaboration among scientists and build a nationwide cohort dedicated to advancing the understanding of cancer disparities, ultimately leading to future R01 projects. Applications can be submitted starting September 16, 2024, with a budget cap of $275,000 over two years, and the closing date for submissions is November 16, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.